Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcus Biosciences (RCUS) EBITDA (2017 - 2025)

Arcus Biosciences has reported EBITDA over the past 9 years, most recently at -$114.0 million for Q4 2025.

  • Quarterly results put EBITDA at -$114.0 million for Q4 2025, down 10.68% from a year ago — trailing twelve months through Dec 2025 was -$386.0 million (down 16.97% YoY), and the annual figure for FY2025 was -$386.0 million, down 16.97%.
  • EBITDA for Q4 2025 was -$114.0 million at Arcus Biosciences, up from -$142.0 million in the prior quarter.
  • Over the last five years, EBITDA for RCUS hit a ceiling of $278.2 million in Q4 2021 and a floor of -$142.0 million in Q3 2025.
  • Median EBITDA over the past 5 years was -$79.0 million (2021), compared with a mean of -$64.3 million.
  • Peak annual rise in EBITDA hit 636.13% in 2021, while the deepest fall reached 4535.53% in 2021.
  • Arcus Biosciences' EBITDA stood at $278.2 million in 2021, then crashed by 126.6% to -$74.0 million in 2022, then dropped by 22.97% to -$91.0 million in 2023, then decreased by 13.19% to -$103.0 million in 2024, then fell by 10.68% to -$114.0 million in 2025.
  • The last three reported values for EBITDA were -$114.0 million (Q4 2025), -$142.0 million (Q3 2025), and -$8.0 million (Q2 2025) per Business Quant data.